Clinical Trial Update: Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABT-450/r/ABT-267 in Japanese adults with genotype 2 chronic HCV; study completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-450/Ritonavir/ABT-267 (ABT-450/ritonavir/ABT-267)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2016-05-13